3SBio Inc Market Cap ($4.38 Billion)
Market Cap & Net Worth: 3SBio Inc (83B)
3SBio Inc market cap. 3SBio Inc (F:83B) has a market capitalization of $4.38 Billion (€3.75 Billion) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #3761 globally and #698 in its home market, demonstrating a -0.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 3SBio Inc's stock price €1.50 by its total outstanding shares 2500652236 (2.50 Billion). Also see 3SBio Inc cash flow conversion for how efficiently the company converts equity into cash flow.
3SBio Inc Market Cap History (2015–2026)
3SBio Inc market cap history from 2015 to 2026. Data shows growth from $1.51 Billion to $4.38 Billion (12.50% CAGR). Check 3SBio Inc (83B) share price today for real-time trading data and today's change.
3SBio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 3SBio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 3SBio Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.44x
3SBio Inc's market cap is 0.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.91x
3SBio Inc's market cap is 0.91 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.08 Billion | $2.80 Billion | $712.56 Million | 0.39x | 1.52x |
| 2017 | $1.93 Billion | $3.73 Billion | $935.39 Million | 0.52x | 2.06x |
| 2018 | $1.36 Billion | $4.58 Billion | $1.28 Billion | 0.30x | 1.07x |
| 2019 | $1.46 Billion | $5.32 Billion | $973.72 Million | 0.28x | 1.50x |
| 2020 | $917.40 Million | $5.59 Billion | $835.79 Million | 0.16x | 1.10x |
| 2021 | $850.75 Million | $6.38 Billion | $1.65 Billion | 0.13x | 0.52x |
| 2022 | $1.73 Billion | $6.86 Billion | $1.91 Billion | 0.25x | 0.91x |
| 2023 | $1.59 Billion | $7.82 Billion | $1.55 Billion | 0.20x | 1.03x |
| 2024 | $2.13 Billion | $9.11 Billion | $2.09 Billion | 0.23x | 1.02x |
| 2025 | $7.72 Billion | $17.70 Billion | $8.48 Billion | 0.44x | 0.91x |
Competitor Companies of 83B by Market Capitalization
Companies near 3SBio Inc in the global market cap rankings as of November 1, 2026. Also see 83B total asset value for a full breakdown of the balance sheet.
Key companies related to 3SBio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of 3SBio Inc (2015–2026)
Market capitalization of 3SBio Inc from 2015 to today. Between 2015 and today, 3SBio Inc's market cap moved from $1.51 Billion to $ 4.38 Billion, with a yearly change of 12.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.38 Billion | -43.23% |
| 2025 | €7.72 Billion | +261.64% |
| 2024 | €2.13 Billion | +33.92% |
| 2023 | €1.59 Billion | -8.05% |
| 2022 | €1.73 Billion | +103.71% |
| 2021 | €850.75 Million | -7.27% |
| 2020 | €917.40 Million | -37.29% |
| 2019 | €1.46 Billion | +7.27% |
| 2018 | €1.36 Billion | -29.28% |
| 2017 | €1.93 Billion | +78.56% |
| 2016 | €1.08 Billion | -28.29% |
| 2015 | €1.51 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of 3SBio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.38 Billion USD |
| MoneyControl | $4.38 Billion USD |
| MarketWatch | $4.38 Billion USD |
| marketcap.company | $4.38 Billion USD |
| Reuters | $4.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 3SBio Inc
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thromboc… Read more